Methods of use of secretory IgA

Patent metadata

Field	Value
Publication number	US-10144773-B2
Application number	US-201615208674-A
Country	US
Kind code	B2
Filing date	Jul 13, 2016
Priority date	Sep 24, 2013
Publication date	Dec 4, 2018
Grant date	Dec 4, 2018

Abstract

Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.

First claim

The invention claimed is:

1. A method of for reducing the risk of inflammation in a barrier surface structure in a mammal in need thereof, comprising orally administering to the mammal an anti-inflammatory amount of secretory IgA, wherein the secretory IgA is isolated from the intestinal luminal fluid or the intestinal mucosa of an animal.

2. The method of claim 1 , wherein the mammal is a human or a non-human mammal.

3. The method of claim 1 , wherein the inflammation is in a barrier surface structure associated with dermatitis.

4. The method of claim 3 , wherein the dermatitis is atopic dermatitis, chronic actinic dermatitis, ulcerative dermatitis, allergic contact dermatitis, or irritant contact dermatitis.

5. The method of claim 4 , wherein the dermatitis is ulcerative dermatitis.

6. The method of claim 5 , wherein the mammal is a C57BL/6 background laboratory mouse.

7. The method of claim 5 , wherein the mammal is a cat at risk of feline ulcerative dermatitis, or a pig at risk of porcine ulcerative dermatitis.

8. The method of claim 1 , wherein the inflammation in a barrier surface structure is associated with an inflammatory disorder that includes chronic gastrointestinal inflammation.

9. The method of claim 8 , wherein inflammatory disorder that includes chronic gastrointestinal inflammation is inflammatory bowel disease, ulcerative colitis, Crohn's disease, lymphocytic or eosinophilic gastroenteritis.

10. The method of claim 9 , wherein the chronic inflammatory disorder is inflammatory bowel disease and the mammal is a dog, a cat or a farmed animal.

11. The method of claim 1 , wherein the mammal is selective serum IgA-deficient, and orally administering IgA reduces the development of inflammatory disorders characterized by inflammation of a barrier surface structure in the mammal.

12. The method of claim 1 , wherein the mammal has allergies, and orally administering IgA reduces the development of inflammatory disorders characterized by inflammation of a barrier surface structure in the mammal.

13. The method of claim 12 , wherein the mammal is a human with a gluten allergy.

14. The method of claim 1 , wherein the mammal is a human with an autoimmune disease.

15. The method of claim 1 , wherein the secretory IgA is isolated from the intestinal luminal fluid or the intestinal mucosa of a pig or a cow.

16. The method of claim 1 , wherein the intestinal mucosa of an animal is stabilized and unhydrolyzed.

17. A method of reducing the risk of and/or treating ulcerative dermatitis in a C57BL/6 background laboratory mouse, comprising orally administering to the C57BL/6 background laboratory mouse an anti-inflammatory amount of secretory IgA.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Cook Mark E
• Sand Jordan Marshall
• Krugner-Higby Lisa Ann
• Ntambi James Mukasa

Classifications

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/10

  characterized by their source of isolation or production · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K16/00 Primary

  Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies · CPC title